Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira ...
(WorldNews Belgium)

· The BE SURE study, comparing bimekizumab to Humira[®] (adalimumab) for the treatment of adults with moderate-to-severe plaque psoriasis, met all co-primary and ranked secondary endpoints · BE SURE is the third Phase 3 bimekizumab psoriasis study to report positive results since October · UCB will submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020 Brussels, Belgium - 06 December 2019, 7:00 AM CET - Regulated Information - Inside Information- UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared the investigational...